AUR-AFE7-TTM1-A-1-1-R-A742-41
— · E
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- E
- subtype
- E
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V1+0.290
- E2F_TARGETS+0.260
- OXIDATIVE_PHOSPHORYLATION+0.250
- G2M_CHECKPOINT+0.220
- SPERMATOGENESIS+0.220
- DNA_REPAIR+0.170
- GLYCOLYSIS+0.130
- MITOTIC_SPINDLE+0.100
- KRAS_SIGNALING_DN+0.060
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.060
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.620
- INTERFERON_GAMMA_RESPONSE-0.520
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.410
- INFLAMMATORY_RESPONSE-0.410
- IL6_JAK_STAT3_SIGNALING-0.400
- ANGIOGENESIS-0.380
- COMPLEMENT-0.370
- KRAS_SIGNALING_UP-0.360
- ALLOGRAFT_REJECTION-0.350
- TNFA_SIGNALING_VIA_NFKB-0.350
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_NKEAAFMW | medulloblastoma | — | 0.911 |
| 2 | SRR8518240 | — | E | 0.907 |
| 3 | BS_9NJHQE9F | medulloblastoma | — | 0.901 |
| 4 | BS_RCC8BXVE | medulloblastoma | — | 0.898 |
| 5 | TCGA-AN-A04D-01A-21R-A034-07 | — | E | 0.894 |
| 6 | AUR-AFE7-TTM3-A-1-1-R-A742-41 | — | E | 0.894 |
| 7 | TCGA-85-8352-01A-31R-2326-07 | — | cohortMD1 | 0.888 |
| 8 | BS_KVNGNETA | medulloblastoma | — | 0.887 |
| 9 | TCGA-UY-A78N-01A-12R-A33J-07 | — | — | 0.884 |
| 10 | TCGA-E7-A5KE-01A-11R-A28M-07 | — | — | 0.882 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 13 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V1 | 0.290 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.260 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.250 | Remibrutinib | — uncovered |
| G2M_CHECKPOINT | 0.220 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.220 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.170 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.130 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.100 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.060 | Remibrutinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.060 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.060 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.050 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.030 | Inavolisib | — uncovered |